BioNeutral's Ygiene Hospital Grade Antimicrobial Passes Sporicidal GLP Test

BioNeutral Group, Inc. (OTCBB: BONU), a specialty chemical technology-based life science company, reports that yesterday it received final test results from ATS Labs indicating that its Ygiene™ Hospital Grade Antimicrobial has passed the stringent Sporicidal GLP test requirements for hospital and medical environment sporicide efficacy claims mandated by the US EPA.

This key test demonstrates that Ygiene™ Hospital Grade Antimicrobial completely eliminates harmful spores. With the completion of this officially required GLP testing, BioNeutral is now positioned to apply for approval of its Ygiene™ Hospital Grade Antimicrobial as a bactericide, fungicide and sporicide with the US EPA. BioNeutral Group intends to proceed with these registrations in consultation with its advisors in order to move forward with the commercialization of its Ygiene™ Hospital Grade Antimicrobial.

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated: “We believe that these new test results show we have a superior sporicide compared to currently available products. With our approvals in the major European countries along with our previous results demonstrating sporicidal efficacy required for Canadian and Australian registration, we are now in a position to move forward in many of the major markets of the world.”